Remyelination News and Research RSS Feed - Remyelination News and Research

Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
Cell transplantation treatment may benefit people with spinal cord injury

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies. [More]
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. [More]
Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. [More]
Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics. [More]
Researchers identify protein that promotes growth of brain cells damaged by MS

Researchers identify protein that promotes growth of brain cells damaged by MS

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth. [More]
LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

Some 2.5 million people around the world have multiple sclerosis (MS), a potentially debilitating disease in which the body's immune system destroys the protective sheath (myelin) that covers nerves. [More]
GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study. [More]
First Direct Measurement Of Spinal Cord Myelin In MS

First Direct Measurement Of Spinal Cord Myelin In MS

... [More]
Wayne State University initiates groundbreaking multiple sclerosis study

Wayne State University initiates groundbreaking multiple sclerosis study

A groundbreaking study in multiple sclerosis focusing on "remyelination in the brain" has been initiated by Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine. [More]
UCSF neuroscientist wins Barancik Prize for multiple sclerosis research

UCSF neuroscientist wins Barancik Prize for multiple sclerosis research

Neuroscientist Jonah Chan, PhD, at the University of California, San Francisco, is the first recipient of a new international prize launched to recognize innovation and progress in multiple sclerosis research. [More]
Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. [More]
Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice. [More]
Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

... [More]
Androgens could constitute an efficient treatment against multiple sclerosis

Androgens could constitute an efficient treatment against multiple sclerosis

Testosterone and its derivatives could constitute an efficient treatment against myelin diseases such as multiple sclerosis, reveals a study by researchers from the Laboratoire d'Imagerie et de Neurosciences Cognitives, in collaboration in particular with the "Neuroprotection et Neurorégénération: Molécules Neuroactives de Petite Taille" unit. [More]
Study examines five varieties of cells after transplantation in the CNS

Study examines five varieties of cells after transplantation in the CNS

When different types of cells are transplanted with the intent of having them aid in repairing central nervous system (CNS) trauma, what is the fate and function of those cells? A Belgian research team carried out research aimed at answering this question by determining how five varieties of cells - neural stem cells, mouse embryonic fibroblasts, dendritic cells, bone marrow mononuclear cells (BMMNCs) and splenocytes - functioned and survived after transplantation in the CNS. [More]
Blocking hyaluronidase activity can help repair brain damage associated with MS

Blocking hyaluronidase activity can help repair brain damage associated with MS

Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders. [More]
Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients. [More]
Gene therapy to promote remyelination in mouse model of MS

Gene therapy to promote remyelination in mouse model of MS

Our bodies are full of tiny superheroes-antibodies that fight foreign invaders, cells that regenerate, and structures that ensure our systems run smoothly. One such structure is myelin-a material that forms a protective, insulating cape around the axons of our nerve cells so that they can send signals quickly and efficiently. But myelin, and the specialized cells called oligodendrocytes that make it, become damaged in demyelinating diseases like multiple sclerosis (MS), leaving neurons without their myelin sheaths. [More]
Study provides hope for stimulating remyelination in MS patients

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life. [More]

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell. [More]